Adamas Pharma Cmn (NASDAQ:ADMS) shares traded 40.06% up during most recent session to reach at the closing price of $19.93. The stock exchanged hands 13.96 Million shares versus average trading capacity of 496.05 Million shares, yielding a market cap of $320.47 Million. Wall Street analysts covering the stock are projecting that the stock will reach $33.83 within the next 52-weeks. The mean target projections are based on 6 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Adamas Pharma Cmn (NASDAQ:ADMS) high price target of $55 and with a conservative view have low price target of $22.

JMP Securities “Maintained” Adamas Pharma Cmn (NASDAQ:ADMS) in a research note issued to investors on 8/25/17 to Market Outperform with price target of $33.

Additionally on 4/01/16 JMP Securities “Initiates Coverage on” Adamas Pharma Cmn (NASDAQ:ADMS) to Market Outperform setting price target at $29 and on 1/19/16 Mizuho “Initiates Coverage on” the stock to Neutral at $26. Furthermore on 1/19/16 Cowen & Co. “Initiates Coverage on” the stock to Outperform at $45.

On the other hand the company has Relative Strength Index (RSI 14) of 71.08 along with Average True Range (ATR 14) of 1.35, Consequently Adamas Pharma Cmn (NASDAQ:ADMS)’s weekly and monthly volatility is 7.19%, 6.12% respectively. The company’s beta value is at 0.93.

In terms of Buy, Sell or Hold recommendations, Adamas Pharma Cmn (NASDAQ:ADMS) has analysts’ mean recommendation of 1.9. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Adamas Pharma Cmn (NASDAQ:ADMS)’s minimum EPS for the current quarter is at $-1.17 and can go high up to $-0.92. The consensus mean EPS for the current quarter is at $-1.01 derived from a total of 5 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.66 earnings per share for the same quarter during last year.

Previously Adamas Pharma Cmn (NASDAQ:ADMS) reported $-0.93 earnings per share (EPS) for the quarter, missing the consensus estimate of $-0.81 by $-0.12. The company posted an earnings surprise of -14.8%.

Currently Adamas Pharma Cmn (NASDAQ:ADMS)’s shares owned by insiders are 1.2%, whereas shares owned by institutional owners are 97.6%. However the six-month change in the insider ownership was recorded -64.8%, as well as three-month change in the institutional ownership was recorded -0.88%.

Adamas Pharma Cmn (NASDAQ:ADMS) 52-week high price stands at $19.50 and low price stands at $12.10, its price distance from 52-week high is 2.21% while its distance from 52-week low price is 64.71%. The stock hit its 52-week high on 08/25/17, and 52-week low on 11/04/16.

Adamas Pharma Cmn (NASDAQ:ADMS)’s trailing twelve month revenues are $200000, whereas its price to sales ratio for the same period is 1602.37. Its book value per share for the most recent quarter is $4.64 while its price to book ratio for the same period is 4.3, as for as the company’s cash per share for the most recent quarter is $7.98, however its price to cash per share ratio for the same period is 2.5. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.